[
    [
        {
            "time": "",
            "orginal_text": "500ETF暂停融券卖出有何深意？",
            "features": {
                "keywords": [
                    "500ETF",
                    "融券",
                    "暂停",
                    "卖出"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "证券"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "500ETF暂停融券卖出有何深意？",
            "scores": {
                "News_content": "500ETF暂停融券卖出有何深意？",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "贝达药业：“恩沙替尼”国内二线治疗上市申报现场核查已完成",
            "features": {
                "keywords": [
                    "贝达药业",
                    "恩沙替尼",
                    "二线治疗",
                    "上市申报",
                    "现场核查"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "贝达药业：“恩沙替尼”国内二线治疗上市申报现场核查已完成",
            "scores": {
                "News_content": "贝达药业：“恩沙替尼”国内二线治疗上市申报现场核查已完成",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]